AGEN:NSD-Agenus Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.51

Change

0.00 (0.00)%

Market Cap

USD 0.67B

Volume

3.53M

Average Target Price

USD 8.00 (+127.92%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD56.71B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

N/A

USD54.24B 20.76 16.02
MRNA Moderna, Inc

N/A

USD43.20B N/A N/A
SGEN Seagen Inc

N/A

USD29.62B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

N/A

USD26.98B 28.36 26.40
RPRX Royalty Pharma plc

N/A

USD25.62B 22.60 9.61
BGNE BeiGene, Ltd

N/A

USD25.22B N/A N/A
BNTX BioNTech SE

N/A

USD24.53B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD23.24B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AGEN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.76% 41% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.76% 41% F 30% F
Trailing 12 Months  
Capital Gain -14.39% 36% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.39% 36% F 27% F
Trailing 5 Years  
Capital Gain -31.58% 52% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.58% 52% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain -0.46% N/A N/A 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.46% N/A N/A 32% F
Risk Return Profile  
Volatility (Standard Deviation) 34.61% N/A N/A 40% F
Risk Adjusted Return -1.32% N/A N/A 32% F
Market Capitalization 0.67B 69% D+ 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -35.73 88% B+ 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 37.87% 96% A 97% A+
Return on Assets -34.78% 36% F 10% F
Debt to Equity Ratio -5.94% 90% A- 94% A
Technical Ratios  
Short Ratio 12.44 16% F 8% F
Short Percent 13.62% 22% F 16% F
Beta 2.10 22% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector